Oleandrin-mediated expression of Fas potentiates apoptosis in tumor cells

Yashin Sreenivasan, Pongali B. Raghavendra, Sunil K. Manna

    Research output: Contribution to journalArticle

    40 Citations (Scopus)

    Abstract

    Chemotherapeutic agent is characterized by its concentration in tumor cells with minimum side effects. Oleandrin, a polyphenolic cardiac glycoside is known to induce apoptosis in tumor cells. However, no report is available on its efficacy in primary cells. In this report we are providing the evidence that oleandrin induces apoptosis, not necrosis in tumor cells but not in primary cells like peripheral blood mononuclear cells (PBMC) and neutrophils. Oleandrin inhibited NF-κB activation in tumor cells but not in primary cells. It induced cell death in NF-κB-overexpressed tumor cells. Oleandrin induced Fas expression thereby inducing apoptosis in tumor cells but not in primary cells. Dominant negative FADD inhibited oleandrin-induced cell death in tumor cells. Overall, these results suggest that oleandrin mediates apoptosis in tumor cells by inducing Fas but not in primary cells indicating its potential anti-cancer property with no or slight side effect.

    Original languageEnglish
    Pages (from-to)308-322
    Number of pages15
    JournalJournal of Clinical Immunology
    Volume26
    Issue number4
    DOIs
    Publication statusPublished - 07-2006

    Fingerprint

    Apoptosis
    Neoplasms
    oleandrin
    Cell Death
    Cardiac Glycosides
    Blood Cells
    Neutrophils
    Necrosis

    All Science Journal Classification (ASJC) codes

    • Immunology
    • Immunology and Allergy

    Cite this

    Sreenivasan, Yashin ; Raghavendra, Pongali B. ; Manna, Sunil K. / Oleandrin-mediated expression of Fas potentiates apoptosis in tumor cells. In: Journal of Clinical Immunology. 2006 ; Vol. 26, No. 4. pp. 308-322.
    @article{5f1f1ea0ab134f8e96f93c6c19372cfe,
    title = "Oleandrin-mediated expression of Fas potentiates apoptosis in tumor cells",
    abstract = "Chemotherapeutic agent is characterized by its concentration in tumor cells with minimum side effects. Oleandrin, a polyphenolic cardiac glycoside is known to induce apoptosis in tumor cells. However, no report is available on its efficacy in primary cells. In this report we are providing the evidence that oleandrin induces apoptosis, not necrosis in tumor cells but not in primary cells like peripheral blood mononuclear cells (PBMC) and neutrophils. Oleandrin inhibited NF-κB activation in tumor cells but not in primary cells. It induced cell death in NF-κB-overexpressed tumor cells. Oleandrin induced Fas expression thereby inducing apoptosis in tumor cells but not in primary cells. Dominant negative FADD inhibited oleandrin-induced cell death in tumor cells. Overall, these results suggest that oleandrin mediates apoptosis in tumor cells by inducing Fas but not in primary cells indicating its potential anti-cancer property with no or slight side effect.",
    author = "Yashin Sreenivasan and Raghavendra, {Pongali B.} and Manna, {Sunil K.}",
    year = "2006",
    month = "7",
    doi = "10.1007/s10875-006-9028-0",
    language = "English",
    volume = "26",
    pages = "308--322",
    journal = "Journal of Clinical Immunology",
    issn = "0271-9142",
    publisher = "Springer New York",
    number = "4",

    }

    Oleandrin-mediated expression of Fas potentiates apoptosis in tumor cells. / Sreenivasan, Yashin; Raghavendra, Pongali B.; Manna, Sunil K.

    In: Journal of Clinical Immunology, Vol. 26, No. 4, 07.2006, p. 308-322.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Oleandrin-mediated expression of Fas potentiates apoptosis in tumor cells

    AU - Sreenivasan, Yashin

    AU - Raghavendra, Pongali B.

    AU - Manna, Sunil K.

    PY - 2006/7

    Y1 - 2006/7

    N2 - Chemotherapeutic agent is characterized by its concentration in tumor cells with minimum side effects. Oleandrin, a polyphenolic cardiac glycoside is known to induce apoptosis in tumor cells. However, no report is available on its efficacy in primary cells. In this report we are providing the evidence that oleandrin induces apoptosis, not necrosis in tumor cells but not in primary cells like peripheral blood mononuclear cells (PBMC) and neutrophils. Oleandrin inhibited NF-κB activation in tumor cells but not in primary cells. It induced cell death in NF-κB-overexpressed tumor cells. Oleandrin induced Fas expression thereby inducing apoptosis in tumor cells but not in primary cells. Dominant negative FADD inhibited oleandrin-induced cell death in tumor cells. Overall, these results suggest that oleandrin mediates apoptosis in tumor cells by inducing Fas but not in primary cells indicating its potential anti-cancer property with no or slight side effect.

    AB - Chemotherapeutic agent is characterized by its concentration in tumor cells with minimum side effects. Oleandrin, a polyphenolic cardiac glycoside is known to induce apoptosis in tumor cells. However, no report is available on its efficacy in primary cells. In this report we are providing the evidence that oleandrin induces apoptosis, not necrosis in tumor cells but not in primary cells like peripheral blood mononuclear cells (PBMC) and neutrophils. Oleandrin inhibited NF-κB activation in tumor cells but not in primary cells. It induced cell death in NF-κB-overexpressed tumor cells. Oleandrin induced Fas expression thereby inducing apoptosis in tumor cells but not in primary cells. Dominant negative FADD inhibited oleandrin-induced cell death in tumor cells. Overall, these results suggest that oleandrin mediates apoptosis in tumor cells by inducing Fas but not in primary cells indicating its potential anti-cancer property with no or slight side effect.

    UR - http://www.scopus.com/inward/record.url?scp=33745913613&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=33745913613&partnerID=8YFLogxK

    U2 - 10.1007/s10875-006-9028-0

    DO - 10.1007/s10875-006-9028-0

    M3 - Article

    C2 - 16779680

    AN - SCOPUS:33745913613

    VL - 26

    SP - 308

    EP - 322

    JO - Journal of Clinical Immunology

    JF - Journal of Clinical Immunology

    SN - 0271-9142

    IS - 4

    ER -